Benitec in the clinic
Friday, 06 June, 2008
Early signs from a Benitec (ASX: BLT) pilot study using RNA interference (RNAi) for AIDS-related lymphoma have proved promising, a panel heard.
Dr John Zaia, chair of the virology division at Beckman Research Institute in California, told attendees at the 11th annual meeting of the American Society of Gene Therapy that the gene treatment was proving to be effective so far.
Patients with AIDS-related lymphoma are being treated using vector-expressed RNAi, aimed at rendering the cells resistant to HIV infection.
Zaia presented data from 60 days of the study on the first two patients. Safe engraftment was seen at 10 days and gene markers are detectable.
According to Benitec, the initial results of this study indicate that if HIV+ patients undertake gene grafting shortly after infection, it could delay their need for antiviral chemotherapy, an invasive and exhausting treatment.
Quitting smoking increases life expectancy even for seniors
Although the benefits of quitting smoking diminish with age, there are still substantial gains...
Stem cell transplants treat blindness in mini pigs
Scientists have successfully transplanted retinas made from stem cells into blind mini pigs,...
Sugary drinks raise cardiovascular disease risk, but occasional sweets don't
Although higher sugar intake raises your risk of certain cardiovascular diseases, consuming sweet...
